Omitting axillary lymph node dissection after positive sentinel lymph node in the post-Z0011 era: Compliance with NCCN and ASCO clinical guidelines and Z0011 criteria in a large prospective cohort
- PMID: 34838310
- DOI: 10.1016/j.bulcan.2021.09.018
Omitting axillary lymph node dissection after positive sentinel lymph node in the post-Z0011 era: Compliance with NCCN and ASCO clinical guidelines and Z0011 criteria in a large prospective cohort
Abstract
Purpose: In the ACOSOG Z0011 trial, patients with primary breast cancer and 1-2 tumor-involved sentinel lymph nodes (SLNs) undergoing breast-conserving surgery had no oncological outcome benefit after axillary lymph node dissection (ALND), despite a relevant rate of non-SLN metastases of 27%. According to the St Gallen expert consensus, and NCCN and ASCO clinical guidelines, ALND may be avoided in patients who meet all ACOSOG Z0011 inclusion criteria. This recommendation can also be extended to patients undergoing mastectomy, with 1 or 2 positive SLNs and an indication for chest wall radiation, in whom axillary radiotherapy can be proposed as an alternative to completion ALND. The aim of this study was to assess non-compliance with the NCCN and ASCO clinical guidelines and Z0011 criteria, namely the rate of performance of completion ALND when it was not recommended, and the rate of failure to perform completion ALND when recommended.
Methods: Data were prospectively analysed from T1-2 N0 breast cancer patients undergoing an SLN procedure and treated at the Georges-François Leclerc Cancer Center between November 2015 and May 2017. Factors associated with non-compliance treatment decisions were identified using logistic regression.
Results: Among 563 patients included, 122 (21.7%) had at least one positive SLN. ALND was not recommended for 76 patients (62.3%), and was recommended in 46 patients (37.7%). The rate of non-compliant treatment was 32% (39/122) overall: ALND was performed despite not being recommended in 16/76 patients (21.1%) and was not performed in 50% of patients in whom it was recommended (23/46). By multivariate analyses, lymphovascular invasion ((Odds Ratio (OR)=6.1; 95% confidence interval (CI): 1.4-26.7; P=0.02)) and only one SLN removed (OR=9.1; 95%CI: 2.2-33.3; P=0.002) were associated with performance of completion ALND when not recommended. Conversely, >1 SLN removed (OR=5.1; 95%CI: 1.2-22.2; P=0.03) was associated with the failure to perform completion ALND when recommended.
Conclusion: Almost one third of patients with invasive breast cancer receive treatment that is not in compliance with recommendations regarding completion ALND.
Keywords: ACOSOG Z0011 Criteria; Breast cancer; Omitting axillary lymph node dissection; Sentinel lymph node.
Copyright © 2021 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.
Similar articles
-
Omission of axillary lymph node dissection for breast cancer patients with three or more positive sentinel lymph nodes.Breast Cancer Res Treat. 2024 May;205(1):127-133. doi: 10.1007/s10549-023-07203-8. Epub 2024 Jan 28. Breast Cancer Res Treat. 2024. PMID: 38281296
-
[Strategies in case of metastatic sentinel lymph node in breast cancer].Bull Cancer. 2020 Jun;107(6):672-685. doi: 10.1016/j.bulcan.2019.09.005. Epub 2019 Nov 4. Bull Cancer. 2020. PMID: 31699399 Review. French.
-
Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.Ann Surg. 2016 Sep;264(3):413-20. doi: 10.1097/SLA.0000000000001863. Ann Surg. 2016. PMID: 27513155 Free PMC article. Clinical Trial.
-
Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.JAMA. 2017 Sep 12;318(10):918-926. doi: 10.1001/jama.2017.11470. JAMA. 2017. PMID: 28898379 Free PMC article. Clinical Trial.
-
Evolution of axillary nodal staging in breast cancer: clinical implications of the ACOSOG Z0011 trial.Cancer Control. 2012 Oct;19(4):267-76. doi: 10.1177/107327481201900403. Cancer Control. 2012. PMID: 23037494 Review.
Cited by
-
Axillary Surgical Attitude Changing with Retrospective Application of ACOSOG Z0011 Eligible Criteria: An Institutional Evaluation.Eur J Breast Health. 2023 Oct 1;19(4):318-324. doi: 10.4274/ejbh.galenos.2023.2023-6-4. eCollection 2023 Oct. Eur J Breast Health. 2023. PMID: 37795004 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical